• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 6:42:35 AM ET
    $CFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CFRX alert in real time by email
    SC 13G/A 1 cfrx-sc13ga_123120.htm AMENDMENT TO FORM SC 13G
     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)* 

     

    ContraFect Corporation

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    212326300

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

     

     

     

    ☒

    Rule 13d-1(c)

     

     

     

     

    ☐

    Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     

    Page 2 of 8

     

    CUSIP No.

    212326300

     

     

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.99%(1)(2)

     

    12

    TYPE OF REPORTING PERSON

    IA, PN

     

     

     

     

     

     

     

     

    (1)

    As more fully described in Item 4, the Warrants are subject to a 4.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blocker.

     

    (2)

    Based on 27,810,082 shares of Common Stock outstanding as of November 6, 2020 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 13, 2020.

     

     

    Page 3 of 8

     

    CUSIP No.

    212326300

     

     

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.99%(1)(2)

     

    12

    TYPE OF REPORTING PERSON

    PN

     

     

     

     

     

     

     

     

    (1)

    As more fully described in Item 4, the Warrants are subject to a 4.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers.

     

    (2)

    Based on 27,810,082 shares of Common Stock outstanding as of November 6, 2020 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 13, 2020.

     

     

    Page 4 of 8

     

    CUSIP No.

    212326300

     

     

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,500,000 shares of Common Stock issuable upon exercise of Warrants(1)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.99%(1)(2)

     

    12

    TYPE OF REPORTING PERSON

    OO

     

     

     

     

     

     

     

     

    (1)

    As more fully described in Item 4, the Warrants are subject to a 4.99% blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers.

     

    (2)

    Based on 27,810,082 shares of Common Stock outstanding as of November 6, 2020 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 13, 2020.

     

     

    Page 5 of 8

     

    CUSIP No.

    212326300

     

     

     

    Item 1(a).

     

    Name of Issuer:                                                         ContraFect Corporation (the “Issuer”)

     

     

     

     

     

     

    Item 1(b).

     

    Address of Issuer’s Principal Executive Offices:   28 Wells Avenue, Third Floor

    Yonkers, New York 10701

     

     

     

    Item 2(a).

     

    Name of Person Filing:   

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund. 

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

     

     

     

    Item 2(b).

     

    Address of Principal Business Office or, if None, Residence:

     

     

    The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019

     

     

     

    Item 2(c).

     

    Citizenship:

     

     

    See Item 4 on the cover page(s) hereto.

     

     

     

    Item 2(d).

     

    Title of Class of Securities:

     

     

    Common Stock, $0.0001 par value (“Common Stock”)

     

     

     

    Item 2(e).

     

    CUSIP Number: 212326300

     

     

     

    Item 3.

    If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

     

    (a)

    ☐

    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

     

    (b)

    ☐

    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

      

     

    Page 6 of 8

     

    CUSIP No.

    212326300

     

     

     

     

     

     

     

    (c)

    ☐

    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    ☐

    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    ☐

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ☐

    A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);

     

     

     

     

     

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    ☐

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4.

    Ownership.

     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 27,810,082 shares of Common Stock outstanding as of November 13, 2020 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 13, 2020.

     

    Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the “Warrant Blocker”). The percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Warrant Blocker. 

     

     

     

    Page 7 of 8

     

    CUSIP No .

    212326300

     

     

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

     

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable

     

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable

     

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable

     

     

    Item 10.

    Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated:

    February 13, 2021

     

     

     

     

     

     

    Altium Capital Management, LP

     

     

     

     

     

     

    By:

    /s/ Jacob Gottlieb

     

     

    Name:

    Jacob Gottlieb

     

     

    Title:

    CEO

     

     

     

     

     

     

    Altium Growth Fund, LP

     

     

     

     

     

     

    By: Altium Growth GP, LLC

     

     

    Its: General Partner

     

     

     

     

     

     

    Signature:

    /s/ Jacob Gottlieb

     

     

    Name:

    Jacob Gottlieb

     

     

    Title:

    Managing Member of Altium Growth GP, LLC

     

     

     

     

     

     

    Altium Growth GP, LLC

     

     

     

     

     

     

    By:

    /s/ Jacob Gottlieb

     

     

    Name:

    Jacob Gottlieb

     

     

    Title:

    Managing Member

     

     

     

     

    Page 8 of 8

     

    EXHIBIT INDEX

     

    EXHIBIT 1:Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

    Members of Group

     

     

     

    Get the next $CFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFRX

    DatePrice TargetRatingAnalyst
    7/14/2022$1.00Outperform → Mkt Perform
    SVB Leerink
    7/14/2022$15.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    2/16/2022$14.00 → $9.00Outperform
    SVB Leerink
    2/2/2022$6.50Speculative Buy → Buy
    WBB Securities
    9/9/2021$14.00Outperform
    SVB Leerink
    More analyst ratings

    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

      YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of

      10/16/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

      YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company's Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. Ambler's presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therap

      9/19/23 8:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

      YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). HABP/VABP are serious, potentially life-threatening infections that are associated with h

      9/18/23 7:30:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

      Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

      5/23/22 8:00:00 AM ET
      $CFRX
      $CLGN
      $ENLV
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer

      Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company's chief financial officer effective August 31, 2021. "We are proud to further bolster our leadership team with the appointment of Josh, who brings to Imvax significant expertise in areas of capital markets and fundraising which will be instrumental to our continued trajectory of growth," said John P. Furey, CEO of Imvax. "I also want to express my profound thanks to Art Howe, co-founder of Imvax and outgoing CFO, for his tireless efforts building the company over the years. We are at a point of exciting momentum as we progress

      8/9/21 8:00:00 AM ET
      $CFRX
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development

      YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Company's early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role i

      6/17/21 7:31:00 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Messinger Michael

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      2/16/23 8:09:36 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Barlow Jane F

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:12:43 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sucoff Cary

      4 - CONTRAFECT Corp (0001478069) (Issuer)

      5/18/22 8:03:32 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ContraFect Corporation

      25-NSE - CONTRAFECT Corp (0001478069) (Subject)

      12/27/23 9:01:56 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - CONTRAFECT Corp (0001478069) (Filer)

      11/15/23 4:41:00 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ContraFect Corporation

      10-Q - CONTRAFECT Corp (0001478069) (Filer)

      11/14/23 4:00:30 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • ContraFect downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded ContraFect from Outperform to Mkt Perform and set a new price target of $1.00

      7/14/22 7:16:02 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ContraFect downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded ContraFect from Overweight to Neutral and set a new price target of $1.00 from $15.00 previously

      7/14/22 7:15:41 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on ContraFect with a new price target

      SVB Leerink reiterated coverage of ContraFect with a rating of Outperform and set a new price target of $9.00 from $14.00 previously

      2/16/22 5:18:49 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      2/14/24 2:24:05 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ContraFect Corporation

      SC 13G - CONTRAFECT Corp (0001478069) (Subject)

      2/14/23 12:22:09 PM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ContraFect Corporation (Amendment)

      SC 13G/A - CONTRAFECT Corp (0001478069) (Subject)

      9/9/22 11:03:32 AM ET
      $CFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care